UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 (Address of principal executive offices) (Zip Code) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTIO ...

| --- | --- | --- | |----------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation June 2020 | | | Forward-Looking Statement MTNB This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Peter Vozzo - Investor Relations Jerry Jabbour - Chief Executive Officer Terry Ferguson - Chief Medical Officer Terri Matkovits - Chief Development Officer Conference Call Participants Bert Hazlett - BTIG Ed Tenthoff - Piper Sandler Jason McCarthy - Maxim Group Greg Fraser - SunTrust Chad Messer - Needham & Company Operator Welcome to the Matinas BioPharma First Quarter 2020 Results Con ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2019 Results Earnings Conference Call March 9, 2020 8:00 AM ET Company Participants Peter Vozzo - Investor Relations Jerry Jabbour - Chief Executive Officer Terry Ferguson - Chief Medical Officer Terry Matkovits - Chief Development Officer Keith Kucinski - Chief Financial Officer. Conference Call Participants Robert Hazlett - BTIG Edward Tenthoff - Piper Sandler Greg Fraser - SunTrust Jason McCarthy - Maxim Group Operator Greetings, and welcome to the Matinas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juris ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q3 2019 Earnings Conference Call November 13, 2019 8:00 AM ET Company Participants Peter Vozzo - Investor Relations Jerry Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Ferguson - Chief Medical Officer Conference Call Participants Jason McCarthy - Maxim Group Gregg Gilbert - SunTrust Robert Hazlett - BTIG Chad Messer - Needham & Company Jerry Isaacson - Roth Capital Operator Greetings, and welcome to the Matinas BioPharma Third ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or ot ...

www.matinasbiopharma.com NYSE AMERICAN: MTNB Corporate Presentation September 2019 Forward-Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than stateme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other j ...